Poster sessions

mesothelioma. In patients with a history of asbestos exposure, radiological imaging can be used to make a diagnosis. Accurate reporting of asbestos related lung disease is of vital importance to national statistics and affected individuals and their families may claim compensation from the government under the industrial injuries disablement benefit scheme. This study set out to examine the adequacy of reporting of asbestos related lung disease to HM coroner in a large teaching hospital.

Methods A retrospective case-note analysis was performed for all deaths occurring whilst under the care of respiratory physicians at a large teaching hospital from July 2012 to February 2013. Electronic patient records and radiological imaging for all of these patients was examined for any evidence of pleural plaques, pleural thickening, asbestos-related lung cancer, asbestosis or mesothelioma. A radiologist had reported all radiological imaging. Records were then cross-referenced with information held by the bereavement care office to identify whether these deaths had been referred to the coroner.

Results 115 patients were identified. Of these, 16 had radiological evidence of asbestos related lung disease; 4 on chest x-ray and 12 on CT. 2 of these patients had biopsy confirmed mesothelioma. Both mesothelioma cases were referred to the coroner and a coroners' inquest subsequently performed. Only 60% of CT proven asbestos related disease and 30% of patients with CXR changes were referred. Of the cases not referred to the coroner 3 patients had bilateral pleural thickening on CXR and 4 patients had CT proven evidence of widespread pleural thickening.

Conclusions This study demonstrates that whilst reporting of malignant asbestos-related pleural disease to the coroner is adequate, there is room for improvement in the reporting of more benign disease. The authors propose that improved education of junior doctors may increase awareness of the importance of asbestos related lung disease, having far-reaching implications for both national statistics and those affected by these conditions.

P208

TAKE UP OF INDUSTRIAL INJURIES DISABLEMENT BENEFITS AND SPIROMETRIC PATTERN ON SUBJECTS WITH ASBESTOS RELATED DIFFUSE PLEURAL THICKENING (DPT)

S Gudur, J Hoyle; North Manchester General Hospital, Manchester, UK

10.1136/thoraxjnl-2013-204457.360

Industrial injuries disablement benefit (IIDB) defines asbestos related diffuse pleural thickening (DPT) with obliteration of a costophrenic angle on chest x-ray as eligible for compensation. Previous studies report significant airflow limitation and functional impairment in these patient.

Methods A database search from 08/2005 to 01/2013 for DPT as agreed by a multi-disciplinary team meeting as fulfilling the criteria for a claim. Any IIDB advice given, records of those who applied, smoking history and lung function tests at presentation were interrogated. Lung function was performed by a specialist cardio-pulmonary technician by body plethysomography. Airflow obstruction defined by ARTP/BTS criteria as FEV1/ FVC <70% and severity of airflow obstruction by FEV1 (50–80% predicted as mild, 30–49% predicted as moderate and <30% as severe obstruction respectively).

Results 39/50 male subjects with DPT attended follow-up.

100% were given written advice of their eligibility to claim

24/39 (62%) who were followed up applied for IIDB, with disability ranging from 15 - 100%. 2 were recorded as having less than 15% disability. Of 15 who did not apply, 4 patients' exposure was not work related and 11 chose not to apply.

4/39 (10%) were never smokers and 30/39 (77%) exsmokers.

Lung function results were available for 43/50 at presentation (table 1).

Conclusions Our group of patients had a significantly high smoking history. Airflow limitation with DPT is the predominant lung function abnormality seen. Despite their disability, patients chose not to apply for IIDB as above.

The airflow limitation may be progressive and hence important to repeat the lung function tests over a time period to see if this deteriorates further contributing to worsening disability.

REFERENCES

1. Abnormal lung function associated with asbestos disease of the pleura, lung and both; comparitive analysis, *Thorax* 1991.

Abstract P208 Table 1. Lung Function patterns.					
Spirometry	Total	%			
Mild obstruction n = 16	20	46.5			
Moderate airflow limitation $n = 4$					
Restriction of airflow	3	7			
Mixed pattern	3	7			
No obstruction	17	39.5			
Total	43	100			

Investigation and management of pleural disease

P209

THE CLINICAL UTILITY OF PLEURAL LYMPHOCYTE SUBSET ANALYSIS IN UNDIAGNOSED EFFUSIONS

¹R Bhatnagar, ¹AO Clive, ²N Zahan-Evans, ²AJ Morley, ³PF Virgo, ²ARL Medford, ²JE Harvey, ⁴CE Hooper, ⁵SH Otton, ⁶M Brett, ¹NA Maskell; ¹University of Bristol Academic Respiratory Unit, Bristol, United Kingdom; ²North Bristol Lung Centre, North Bristol NHS Trust, Bristol, United Kingdom; ³Department of Biochemistry, North Bristol NHS Trust, Bristol, United Kingdom; ⁴Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom; ⁵Department of Haematology, North Bristol NHS Trust, Bristol, United Kingdom; ⁶Department of Cellular Pathology, North Bristol NHS Trust, Bristol, United Kingdom

10.1136/thoraxjnl-2013-204457.361

Introduction Blood and tissue lymphocyte subsets (LS) analysis are routinely used in the diagnosis of a number of haematological conditions. Samples cost £25 to process and are technically labour intensive. The 2010 BTS pleural guidelines suggest LS may be useful in cases of suspected lymphoma, but there is no evidence supporting their utility or position in pleural diagnostic algorithms.

Methods Using a prospectively-maintained database of all undiagnosed pleural effusions, we analysed patients presenting to our service from 2009–2011. Fluid was initially sent for cytology and cell differential. Patients with $\geq 50\%$ fluid lymphocytes at first sampling, with no definite cytological evidence of carcinoma, and who underwent a further pleural procedure, had

A170 Thorax 2013;68(Suppl 3):A1–A220

a second sample sent for LS analysis. The cause of the original effusion was agreed by two independent consultants after a minimum 12 month follow-up period.

Results 395 patients with undiagnosed effusions were seen, of which 124(31%) were found to be lymphocytic on initial examination. 35(28.2%) patients were excluded due to confirmed (non-haematological) malignancy (11 initial cytology, 24 biopsy). A further 46(37.1%) patients were excluded with confirmed benign diagnoses including inflammatory pleuritis, heart failure and pleural infection. 39/43 (90.7%) patients therefore had samples sent for LS analysis.

7/43 (16.3%) patients' effusions were diagnosed at 12 months as primarily due to lymphoma, with 5 having a previous diagnosis of such. Their characteristics are described in the table below.

LS analysis was diagnostic in 4 and negative in 35 cases. There were no false positive results. Therefore, based on these data, for determining whether there is haematological malignancy in lymphocytic pleural fluid, LS analysis has a sensitivity of 57.1%, a specificity of 100%, and a positive and negative predictive value of 100% and 91.4% respectively.

Conclusions LS analysis appears useful in a selected subgroup of patients presenting with undiagnosed effusions. It should only be considered in those patients with a lymphocytic effusion which shows negative initial cytology and/or no firm diagnosis established on pleural biopsy, or those with a past medical history of a lymphoma. A negative LS result does not exclude the possibility of a haematological cause for the effusion.

Abstract P209 Table 1. Investigations and characteristics of patients with confirmed lymphoma who underwent pleural fluid lymphocyte subsets analysis.

Patient	Disease	Comorbidities	History of	LS	Tissue	Tissue
			lymphoma	positive	obtained	diagnostic?
1	DLBCL	Nil	No	No	Marrow	Yes
2	DLBCL	AF	Yes	Yes	Marrow	No
3	DLBCL	CCF, AF	Yes	No	Node	Yes
4	Low grade	Nil	Yes	Yes	Too frail	
	NHL					
5	Low grade	Nil	Yes	No	Too frail	
	NHL					
6	CLL	Nil	Yes	Yes	No	
7	CLL	T2DM, AF	No	Yes	Thoracoscopy	Yes

DLBCL=Diffuse large B-cell Lymphoma, NHL=Non-Hodgkin's Lymphoma, CLL=Chronic Lymphocytic Leukaemia

P210

DEFINING THE MINIMAL IMPORTANT DIFFERENCE FOR THE VISUAL ANALOGUE SCALE FOR DYSPNOEA IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS

¹EK Mishra, ¹J Corcoran, ¹R Hallifax, ¹J Stradling, ²N Maskell, ¹N Rahman; ¹University of Oxford, Oxford, UK; ²University of Bristol, Bristol, UK

10.1136/thoraxjnl-2013-204457.362

Background Malignant pleural effusions (MPEs) cause disabling dyspnoea in over 1 million people worldwide per year. Currently recruiting and recently reported randomised controlled trials (RCTs) use the visual analogue scale for dyspnoea (VASD) to assess mean daily breathlessness in patients with MPEs (ISRCTN12852177, ISRCTN4784593, ISRCTN73255764) in order to provide evidence for the optimal method of symptom palliation. The VASD consists of a 100 mm line which subjects mark at a point representing their dyspnoea intensity.

Determination of the minimal important difference (MID) for the VASD in patients with MPEs is essential to interpret the results of these trials.

Methods Patients with a confirmed or suspected MPE undergoing a pleural procedure recorded their baseline VASD prior to the procedure and, 24 hours later, their post-procedure VASD and assessed their dyspnoea on a 7 point Likert scale. Age, gender, diagnosis, procedure performed and volume of fluid drained were also recorded.

Results A total of 114/123 (93%) questionnaires were returned. Mean age of respondents was 70 years and 56% were female. Commonest malignancies were breast (41%), mesothelioma (26%) and non-small cell lung cancer (18%). Procedures included: therapeutic aspiration (35%), medical thoracoscopy (27%), chest drain insertion (11%), diagnostic tap (11%) and indwelling pleural catheter insertion (8.8%). The mean decrease in VASD in patients reporting a 'small but just worthwhile decrease' in their dyspnoea (i.e. equivalent to the MID) was 19mm (95% CI 14–24 mm). The volume of fluid required to drain to produce a change in VASD of 19mm was 760ml. Mean decrease in VASD for the different procedures were: chest drain 41mm; IPC insertion and drainage 41mm; therapeutic aspiration 31mm; diagnostic aspiration 19mm; and LAT 24mm.

Conclusion The MID for the VASD in patients with a MPE undergoing a pleural procedure is 19mm (95% CI 14–24mm). This value should be used when interpreting the results of RCTs in patients with MPEs using the VASD as an outcome measure and to calculate the sample size for future RCTs.

P211

DOMICILIARY CARE OF PATIENTS WITH PRIMARY AND SECONDARY PNEUMOTHORACES: OUR EXPERIENCE IN AYRSHIRE, PATIENT SATISFACTION AND HEALTH ECONOMIC ANALYSIS

¹A Guhan, ¹S Learmonth, ²O Moseley, ¹D Sword, ¹F Kelly; ¹University Hospital Ayr, NHS Ayrshire and Arran, Ayr, United Kingdom; ²NHS Ayrshire and Arran, Ayr, United Kingdom

10.1136/thoraxjnl-2013-204457.363

Background Domiciliary care (DC) of Spontaneous Pneumothoraces (SP) with an ambulatory Heimlich Valve (HV) attached to the Intercostal Chest Drain (ICD) has potential for carecloser-to-home, avoiding hospitalisation and saving healthcare resources. Wider acceptance of this practice requires demonstration of tangible benefits in terms of patient safety, patient satisfaction and cost savings.

Method In the last year (since July 2012), we established a consultant-led DC service for SP at the University Hospital Ayr, Ayrshire. All primary (PSP) or secondary (SSP) SP admitted through The Emergency Department (ED) were assessed within 48 hours for potential DC with informed consent, based on presence of Persistent Air Leak and predetermined criteria ensuring patient safety (Table:1). All DC patients had 72 hourly consultant ward reviews (CWR) with chest Xray or sooner should patients identify HV non-movement with coughing. ICD was removed when SP resolved. SP patients on DC were readmitted if concerns were identified. Patient satisfaction was assessed formally (Table 6).

Health economics: Costs were calculated from an NHS perspective by examining resource use associated with DC for SP. This figure was then compared against the potential cost-avoidance in terms of respiratory medicine bed days saved. Costs were taken from published ISD reference costs when available and local

Thorax 2013;68(Suppl 3):A1-A220